trending Market Intelligence /marketintelligence/en/news-insights/trending/-30QnnR3HdPEMQH9Tdej7g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Genera Biosystems' entitlement offer fails to garner enough interest from buyers

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Genera Biosystems' entitlement offer fails to garner enough interest from buyers

Genera Biosystems Ltd. said it fell short of the minimum subscriptions required to proceed with its previously announced entitlement offer of ordinary shares.

Under the 4-for-5 non-renounceable entitlements issue, the Australian molecular diagnostics company expected to raise approximately A$11.4 million by issuing 88,049,453 shares.

However, Genera Biosystems said it received applications for a total of 1,869,712 ordinary shares for a total subscription amount of A$243,062.

The company said this represents a shortfall in subscriptions of 86,179,833 shares and it plans to wait until April 30 to meet the minimum subscription level.

In case the minimum threshold is not met, the company will repay all application amounts in full without interest.